Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iqvia Holdings Inc (NY: IQV )

235.20 -5.67 (-2.35%)
Official Closing Price Updated: 4:10 PM EDT, Sep 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Iqvia Holdings Inc

< Previous 1 2 3 4 5 6 Next >
Datadog, IQVIA, Organon And An Oilfield Services Giant Rolling Out An AI Platform: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors said he likes IQVIA Holdings Inc. (NYSE: IQV) 
Via Benzinga
Here's How Much $1000 Invested In IQVIA Hldgs 5 Years Ago Would Be Worth Today
Via Benzinga
Here's How Much $1000 Invested In IQVIA Hldgs 5 Years Ago Would Be Worth Today
Via Benzinga
$1000 Invested In IQVIA Hldgs 5 Years Ago Would Be Worth This Much Today
Via Benzinga
2 Soaring Healthcare Stocks That Could Climb Even Higher
These stocks are coming off a big week that could be the beginning of a bigger rally. 
Via The Motley Fool
Is Veeva Systems a Buy Now?
The stock is trading at a high multiple despite revenue that's growing by mid-single-digit percentages. 
Via The Motley Fool
Here's How Much $1000 Invested In IQVIA Hldgs 5 Years Ago Would Be Worth Today
Via Benzinga
IQVIA Hldgs's Return On Capital Employed Overview
Via Benzinga
Expert Ratings for IQVIA Hldgs
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today
Via Benzinga
This Foreboding Sign Looms Over IQVIA Hldgs's Chart
Via Benzinga
Death Cross Looms Over IQVIA Hldgs Investors
Via Benzinga
The Latest Analyst Ratings for IQVIA Hldgs
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
Via Benzinga
Here's How Much You Would Have Made Owning IQVIA Hldgs Stock In The Last 5 Years
Via Benzinga
2 Clinical Research Stocks That Could Grow by More Than 10% This Year, and 1 to Watch
These companies strive to bring down the cost of developing new therapies. 
Via The Motley Fool
(IQV) - Analyzing IQVIA Hldgs's Short Interest
Via Benzinga
What 6 Analyst Ratings Have To Say About IQVIA Hldgs
Via Benzinga
Here's How Much $100 Invested In IQVIA Hldgs 5 Years Ago Would Be Worth Today
Via Benzinga
Where IQVIA Hldgs Stands With Analysts
Via Benzinga
IQVIA Clocks 2.8% Sales Growth In Q4, Beats Street View By A Whisker
Via Benzinga
Earnings Outlook For IQVIA Holdings
Via Benzinga
Will Investors Notice Exciting Sign On IQVIA Hldgs's Chart?
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
Via Benzinga
MannKind To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Monday
Piper Sandler cut the price target for CS Disco, Inc. (NYSE: LAW) from $11 to $7.5. Piper Sandler analyst Arvind Ramnani downgraded the stock from Overweight to Neutral. CS Disco shares fell 1.2% to... 
Via Benzinga
Got $300? 3 Growth Stocks to Buy That Could Double Your Money
All three companies have shown consistent revenue and EPS growth. 
Via The Motley Fool
7 Hot Healthcare Stocks With the Potential to Outperform
These healthcare stocks to buy now have the potential to outperform the market over the long-term because their businesses are strong. 
Via InvestorPlace
PayPal, Global Payments And 3 Stocks To Watch Heading Into Friday
With US futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Investor Optimism Declines Slightly As Dow Drops 250 Points
The CNN Money Fear and Greed index showed some decline in the overall sentiment among US investors. US stocks closed lower on Thursday as investors assessed recent batch of corporate earnings. 
Via Benzinga
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
These companies are changing their industries. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.